ClinicalTrials.Veeva

Menu

Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients

S

Sohag University

Status

Enrolling

Conditions

Lupus Nephritis

Treatments

Diagnostic Test: renal doppler

Study type

Observational

Funder types

Other

Identifiers

NCT06631404
Soh-Med-24-09-07MS

Details and patient eligibility

About

Systemic Lupus Erthymatosous (SLE) is achronic inflammatory multi system auto immue disease characterized by pathogenic auto anti bodies production against nuclear structures (Bolouri et al.,2022), SLE affecting mainly woemn of childbearing age and is chracterized by unpredictable flares and remissions , disease variety varied from mild episode disorder to arpidly progressive life -threatening illness..

LN is diagnosed by either the presence of proteinuria >0.5g/day. active urinary sediment , or an unexplained rise in serum creatinine there fore , identifying new invasive biomarkers of LN severity and outcome is mandatory, Renal Arterial resistive index ( RRI) is anon invasive biomarker that has been studied as apotential indicator of disease activity in LN patients.

Enrollment

55 estimated patients

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged ≥18 years.
  • SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls.
  • Patients cooperative and can answer questions.
  • Patients who are able and willing to give written informed consent.

Exclusion criteria

  • • Individuals with other autoimmune diseases.

    • Diabetes.
    • Hypertension.
    • Heart failure.
    • Hepatic diseases.
    • Chronic renal failure.
    • Renal artery stenosis.
    • Renal vein thrombosis.
    • Intrarenal arteriovenous fistula.
    • Obstructive nephropathy.
    • Urinary tract obstruction that could affect RI of intra renal arteries.
    • Un cooperative patients.
    • Patients not able and willing to give written informed consent.

Trial design

55 participants in 2 patient groups

group SLE
Description:
Patients with SLE
Treatment:
Diagnostic Test: renal doppler
group control
Description:
matched healthy subjects
Treatment:
Diagnostic Test: renal doppler

Trial contacts and locations

1

Loading...

Central trial contact

Esam M Abualfadl, professor; Doaa R Abdelkarim, resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems